Septabene Munnholsúði, lausn 1,5 mg/ml+5 mg/ml আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

septabene munnholsúði, lausn 1,5 mg/ml+5 mg/ml

krka, d.d., novo mesto - benzydaminum hýdróklóríð; cetylpyridinii chloridum - munnholsúði, lausn - 1,5 mg/ml+5 mg/ml

Septabene citron og honning Munnsogstafla 3 mg/1 mg আইসলণ্ড - আইসল্যান্ডীয় - LYFJASTOFNUN (Icelandic Medicines Agency)

septabene citron og honning munnsogstafla 3 mg/1 mg

krka, d.d., novo mesto - benzydaminum hýdróklóríð; cetylpyridinii chloridum - munnsogstafla - 3 mg/1 mg

Sapropterin Dipharma ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

sapropterin dipharma

dipharma arzneimittel gmbh - sapropterin díhýdróklóríð - phenylketonurias - Önnur meltingarvegi og efnaskipti vörur, - sapropterin dipharma is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment. sapropterin dipharma is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.

Cuprior ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

cuprior

gmp-orphan sa - trientine tetrahydrochloride - hepatolenticular hrörnun - Önnur meltingarvegi og efnaskipti vörur, - cuprior er ætlað fyrir meðferð wilson er sjúkdómur í fullorðnir, unglingum og börn sem stóð 5 ár með óþol fyrir d-penicillamíns meðferð.

Orladeyo ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

orladeyo

biocryst ireland limited - berotralstat dihydrochloride - ofsabjúgur, arfgengur - other hematological agents - orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in adult and adolescent patients aged 12 years and older.

Inrebic ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

inrebic

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - Æxlishemjandi lyf - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Tabrecta ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

tabrecta

novartis europharm limited  - capmatinib dihydrochloride monohydrate - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Vanflyta ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

vanflyta

daiichi sankyo europe gmbh - quizartinib dihydrochloride - kyrningahvítblæði, mergbólga - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.

Cholestagel ইউরোপীয় ইউনিয়ন - আইসল্যান্ডীয় - EMA (European Medicines Agency)

cholestagel

cheplapharm arzneimittel gmbh - colesevelam (as hydrochloride) - kólesterólhækkun - lipid breytandi lyf - samhliða co-gefið með 3-hýdroxý-3-metýl-glutaryl-kóensím-(hmg-str)-redúktasa hemil (statín) er fram eins og venjulega meðferð til að mataræði til að veita viðbót lækkun í lítilli þéttleika-lípóprótein-kólesterólið (gegn-c) stigum í fullorðinn sjúklinga með aðal hypercholesterolaemia sem eru ekki nægilega stjórnað með statín einn. samhliða eitt og sér kemur fram eins og venjulega meðferð til að mataræði fyrir lækkun hækkuðum kólesteról og gegn-c í fullorðinn sjúklinga með aðal hypercholesterolaemia, í hvern cholestagel er talið óviðeigandi eða er ekki vel. samhliða getur líka verið notuð í ásamt ezetimibe, með eða án statín, í fullorðinn sjúklinga með aðal hypercholesterolaemia, þar á meðal sjúklinga með ættingja hypercholesterolaemia (sjá kafla 5.